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Pulmonary metastasetomy is known to be able to improve the survival 
in selected patients with metastatic lung disease. We analyzed the short 
term treatment results of simultaneous multitarget irradiation using 
tomotherapy in the primary or secondary lung cancer patients to know 
whether radiation therapy could substitute pulmonary operation. We 
treated thirty two patients using tomotherapy for 1 year after our ma-
chine installation in 2005. The original malignancies were hepatocel-
luar carcinoma, lung cancer, breast cancer, colorectal cancer, invasive 
thymoma, thyroid cancer, pancreas cancer, endometrial cancer, renal 
cell carcinoma, oral cavity cancer and Ewing’s sarcoma. The average 
number of pulmonary targets was 5.1 (range: 1-15). The unilateral pul-
monary lesions were in eleven patients (34.4%) and bilateral lesions in 
21 patients (65.6%). In 12 patients (37.5%), synchronous extrapulmo-
nary targets were present. Twenty six patients (81.3%) had been treated 
with chemotherapy for pulmonary metastasis before tomotherapy. The 
median number of cycles of systemic chemotherapy was nine (range 
1- 21) and the median interval between chemotherapy and tomotherapy 
was 2 months (range: 1-36 months). Four patients (12.5%) had a past 
history of mediastinal radiotherapy. We immobilized the patients with 
BodyFix system (Medical Intelligence, Germany) and deﬁned the 
GTV (gross tumor volume) and PTV (planning target volume: GTV + 
0.5 ~ 1.5cm) in chest CT scan and their median doses were 50.0±5.99 
Gy and 40.0±7.03 Gy with 3-20 fractionations, respectively. Median 
treatment duration was 14days (range: 3-28 days). Before treatment, we 
always conﬁrmed the positions of the targets and the isodose distri-
bution after checking megavoltage CT scan. To decrease the risk of 
pulmonary toxicity, we tried to decrease the values of mean lung dose, 
median lung dose and V25 as low as possible. RECIST (Response 
Evaluation Criteria In Solid Tumors) method and CTCAE (Common 
Terminology Criteria for Adverse Event) method were used to evaluate 
the post-treatment response and pulmonary toxicity. The number of 
eligible patients was thirty (93.8%) whom we could follow up more 
than 1 month. Median follow up period was 6 month (1-13 months). 
The rates of complete and partial response were 3.3% and 46.7% in 1 
month and 15.6% and 36.7% in 3 months after treatment. The over-
all response rate was 52.3% in 3 months after treatment. The data of 
pulmonary dosimetric analysis were that in right and left lung, mean 
lung doses were 13.89±6.70 Gy and 15.20±5.44 Gy, median lung doses 
were 12.52±6.27 Gy and 13.43±6.00 Gy and the values of V25 were 
13.76±10.04% and 15.25±8.77%. Radiation pneumonitis or pulmonary 
ﬁbrosis was appeared in 10 patients (33.3%) but all pulmonary toxici-
ties were less than grade III. We can suggest that tomotherapy for mul-
tiple lung metastasis was a safe and effective treatment modality but we 
need study about further analysis of survivals, chronic complications 
and inﬂuencing factors through long term follow up in larger group of 
patients to make up the limitation of our experience.
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Rationale: Pleural effusions have classically been divided into transu-
dates and exudates. If it is exudative, more diagnostic tests are required 
in order to determine the cause of the local disease. Malignancy is a 
common and important cause of exudative pleural effusions. Because 
pleural ﬂuid cytology and pleural biopsy specimens do not provide a 
diagnosis in a high percentage of malignant effusions, several tumor 
markers have been studied. To overcome this limitation, we hypoth-
esized that measurement of melanoma antigen gene (MAGE) would be 
useful in differentiating between benign and malignant effusion. 
Methods: We studied prospectively 127 consecutive patients with 
pleural effusion (malignant 42, tuberculous 27, parapneumonic 17, 
empyema 5, transudative 21, miscellaneous 3, nondiagnostic 12). We 
examined standard parameters of pleural effusion and measured the 
expression of MAGE and cytology with the obtained pleural effusion. 
Expression of MAGE was interpreted by means of a commercial kit 
using RT-PCR method. 
Results: The sensitivity and speciﬁcity of cytology were 45.2% and 
100% respectively and the positive predictive value and negative pre-
dictive value of cytology were also 100% and 76.0% respectively. The 
sensitivity and speciﬁcity of MAGE were 27.0% and 98.5% respec-
tively and the positive predictive value and negative predictive value of 
MAGE were also 90.9% and 71.3% respectively. Using the cutoff value 
of 3 μg/L for CEA, the combination of MAGE and CEA in pleural 
ﬂuid revealed 71.4% sensitivity and 89.0% speciﬁcity in diagnosis of 
malignant pleural effusion. 
Conclusions: The ﬁndings of this study suggest that the combination 
of MAGE and CEA in addition with pleural ﬂuid cytology would be 
useful as a diagnostic marker in differentiating between benign and 
malignant pleural effusion.
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Surgical Therapy of Malignant Pleural Mesothelioma: A Single 
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Introduction: Few patients with malignant pleural mesothelioma 
(MPM) are candidates for surgical treatment. Since it is almost impos-
sible to achieve a R0-resection, surgery has been combined with other 
treatment modalities. In this retrospective study, the results of surgical 
therapy as part of two different therapeutic regimens were investigated. 
Materials and Methods: Between 2002 and 2005, 15 MPM patients 
were treated with ExtraPleural Pneumonectomy (EPP/TRT) and 
postoperative hemi-Thoracic RadioTherapy (54 Gy). Previously (1999-
2001), 20 patients underwent a combination of cytoreductive surgery 
- pleurectomy (12) or EPP (8) - and Hyperthermic IntraTHOracic 
Chemotherapy (HITHOC) with cisplatin and doxorubicin, followed by 
radiotherapy to the thoracotomy scar and drainage tracts (24 Gy). 
